1-(4-nitrophenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one | 939772-66-4

• 英文名称: 1-(4-nitrophenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one
• CAS: 939772-66-4
• 化学式: C₂₆H₃₃N₃O₄
• 分子量: 451.566
• InChiKey: KEXHKWAEVXTLPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.87
• 重原子数：
  33.0
• 可旋转键数：
  10.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.92
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1-(4-nitrophenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one 在 甲烷磺酸 、 盐酸 、 溴甲酚绿 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 (6R,10bS)-6-(4-nitrophenyl)-9-(3-piperidin-1-ylpropoxy)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline
  参考文献：
  名称：

  Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

  摘要：

  A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.106
• 作为产物：
  描述：

  1-{3-[3-(4,5-dihydro-3H-pyrrol-2-yl)-phenoxy]-propyl}-piperidine 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.5h， 生成 1-(4-nitrophenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one
  参考文献：
  名称：

  Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

  摘要：

  A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.106